GLPwatch
Potential use of exenatide for the treatment of obesity.
Expert Opin Investig Drugs · 2011
Last updated 2026-05-28Exenatide is a drug being studied for obesity treatment, particularly in people with type 2 diabetes. It works by helping to reduce food intake, though this effect may not last beyond 6 months without additional therapy. The drug is being considered as a possible option, potentially alongside other hormones like leptin and amylin.
AI summary of the abstract below.
| Journal | Expert Opin Investig Drugs, 2011 |
|---|---|
| Citations | 21 |
| Relative citation ratio | 0.57 |
| NIH percentile | 33 |
| Molecules | exenatide |
| Conditions studied | Obesity |
Abstract
INTRODUCTION: Obesity is a major health threat in the Western world because of its high incidence and prevalence, and its association with metabolic and cardiovascular disease as well as cancer. The reduction of food intake in obese patients can be achieved only transiently (generally for no longer than 6 months), in the absence of concomitant pharmacological therapy. Only bariatric surgery provides a means to increase satiety and/or decrease nutrient absorption in obese patients, in the long term.
AREAS COVERED: This article reviews the available pharmacological treatments for obesity as well as the pharmacology and mechanism of action of exenatide in obese type 2 diabetic patients.
EXPERT OPINION: Exenatide is a potential new candidate treatment for obesity, possibly in combination with other hormones that increase satiety (leptin) and slow gastric emptying (amylin).
Verbatim abstract via PubMed 22017240 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.